{
    "clinical_study": {
        "@rank": "11867", 
        "arm_group": [
            {
                "arm_group_label": "Darbepoetin alfa SC", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Darbepoetin alfa IV", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is investigating darbepoetin alfa for the treatment of anemia in patients with\n      non-myeloid cancers who are receiving chemotherapy.  Darbepoetin alfa is a recombinant\n      protein that stimulates the production of red blood cells.  In this study, darbepoetin alfa\n      will be administered as either an injection under the skin (subcutaneously) or directly into\n      a vein (intravenously)."
        }, 
        "brief_title": "Chemotherapy Related Anemia", 
        "completion_date": {
            "#text": "April 2003", 
            "@type": "Actual"
        }, 
        "condition": [
            "Anemia", 
            "Non-Myeloid Malignancies"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Anemia", 
                "Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosed with a non-myeloid malignancy\n\n          -  Scheduled to receive a minimum of an additional 12 weeks of chemotherapy from the\n             time of first dose of study drug\n\n          -  Screening hemoglobin concentration less than or equal to 11.0g/dL\n\n          -  ECOG performance status of 0 to 2\n\n          -  Adequate renal and liver function\n\n        Exclusion Criteria:\n\n          -  History of seizure disorder\n\n          -  Received recombinant human erythropoietin (rHuEPO) or darbepoetin alfa therapy within\n             4 weeks before study day 1\n\n          -  More than 2 red blood cell transfusions within 4 weeks before study day 1, or any red\n             blood cell transfusion within 14 days before study day 1"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 3, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00035607", 
            "org_study_id": "20010199"
        }, 
        "intervention": [
            {
                "arm_group_label": "Darbepoetin alfa SC", 
                "description": "Subcutaneous (SC) injection of darbepoetin alfa at 4.5 mcg/kg weekly for weeks 1-6, then 4.5 mcg/kg Q3W", 
                "intervention_name": "Darbepoetin alfa SC", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Darbepoetin alfa IV", 
                "description": "Intravenous administration of darbepoetin alfa at 4.5 mcg/kg weekly for weeks 1-6, then 4.5 mcg/kg Q3W", 
                "intervention_name": "Darbepoetin alfa IV", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Darbepoetin alfa"
        }, 
        "lastchanged_date": "May 9, 2013", 
        "link": [
            {
                "description": "AmgenTrials clinical trials website", 
                "url": "http://www.amgentrials.com"
            }, 
            {
                "description": "Notice regarding posted summaries of trial results", 
                "url": "http://download.veritasmedicine.com/REGFILES/amgen/Amgen_results_disclaimer.pdf"
            }, 
            {
                "description": "To access clinical trial results information click on this link", 
                "url": "http://download.veritasmedicine.com/REGFILES/amgen/08D_FDAMA_113_Posting_Summary_33_NESP_20010199.pdf"
            }, 
            {
                "description": "FDA-approved Drug Labeling", 
                "url": "http://www.aranesp.com/"
            }
        ], 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Open-label, Multicenter Study of Subcutaneous and Intravenous Administration of Darbepoetin Alfa (Novel Erythropoiesis Stimulating Protein, NESP) for the Treatment of Anemia in Subjects With Non-myeloid Malignancies Receiving Multicycle Chemotherapy", 
        "overall_official": {
            "affiliation": "Amgen", 
            "last_name": "MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2002", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Change in hemoglobin concentration measured from baseline to the end of treatment period (EOTP)", 
            "safety_issue": "No", 
            "time_frame": "from baseline to the end of treatment period (EOTP)"
        }, 
        "removed_countries": {
            "country": "United States"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00035607"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "results_reference": {
            "PMID": "15860486", 
            "citation": "Justice G, Kessler JF, Jadeja J, Campos L, Weick J, Chen CF, Heatherington AC, Amado RG. A randomized, multicenter study of subcutaneous and intravenous darbepoetin alfa for the treatment of chemotherapy-induced anemia. Ann Oncol. 2005 Jul;16(7):1192-8. Epub 2005 Apr 28."
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage of subjects who have a rapid rise in hemoglobin concentration; negative clinical consequences potentially associated with this rise evaluated in subjects with and without a rapid rise in hemoglobin concentration", 
                "safety_issue": "Yes", 
                "time_frame": "throughout study"
            }, 
            {
                "measure": "Change in hemoglobin concentration measured from baseline to week 7 and from week 7 to EOTP", 
                "safety_issue": "No", 
                "time_frame": "from baseline to week 7 and from week 7 to EOTP"
            }, 
            {
                "measure": "Time to and percentage of subjects who achieve hemoglobin improvement during the treatment period", 
                "safety_issue": "No", 
                "time_frame": "during the treatment period"
            }, 
            {
                "measure": "Time to and percentage of subjects with a hemoglobin response during the treatment period", 
                "safety_issue": "No", 
                "time_frame": "during the treatment period"
            }, 
            {
                "measure": "Percentage of subjects who exceed the hemoglobin threshold", 
                "safety_issue": "Yes", 
                "time_frame": "throughout study"
            }, 
            {
                "measure": "Incidence of all adverse events, serious adverse events, and severe or life-threatening adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "throughout study"
            }, 
            {
                "measure": "Incidence, if any, of neutralizing antibody formation to darbepoetin alfa", 
                "safety_issue": "Yes", 
                "time_frame": "throughout study"
            }
        ], 
        "source": "Amgen", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Amgen", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2001", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }, 
    "geocoordinates": {}
}